

## Bibliografia

1. Bousquet J, Arnavelhe S, Bedbrook A, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. *Clin Transl Allergy.* 2018;8(1).
2. Bousquet J, Bedbrook A, Czarlewski W, et al. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. *Clin Transl Allergy.* 2019;9(1).
3. Brozek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. *J Allergy Clin Immunol.* 2017;140(4):950-958.
4. De Marco R, Cappa V, Accordini S, et al. Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. *Eur Respir J.* 2012.
5. Quercia O, Incorvaia C, Puccinelli P, et al. Prevalence of allergic disorders in Italy: the Cotignola population study. *Eur Ann Allergy Clin Immunol.* 2012;44(1):5-11.
6. Marcellusi A, Viti R, Incorvaia C, Burastero SE, Mennini FS. Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study. *Recenti Prog Med.* 2015;106(10):517-527.
7. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA 2 LEN and AllerGen). *Allergy Eur J Allergy Clin Immunol.* 2008;63(SUPPL. 86):8-160.
8. Gilles S, Akdis C, Lauener R, et al. The role of environmental factors in allergy: A critical reappraisal. *Exp Dermatol.* 2018;27(11):1193-1200.
9. D'Amato G, Holgate ST, Pawankar R, et al. Meteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy Organization. *World Allergy Organ J.* 2015;8(1).
10. Bousquet J, Dahl R, Khaltaev N. Global Alliance against Chronic Respiratory Diseases. *Allergy Eur J Allergy Clin Immunol.* 2007;62(3):216-223.
11. De Marco R, Poli A, Ferrari M, et al. The impact of climate and traffic-related NO<sub>2</sub> on the prevalence of asthma and allergic rhinitis in Italy. *Clin Exp Allergy.* 2002;32(10):1405-1412.
12. Dykewicz MS, Wallace D V, Baroody F, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. *Ann Allergy, Asthma Immunol.* 2017;119(6):489-511.e41.
13. Bousquet J, Meltzer EO, Couroux P, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. *J Allergy Clin Immunol Pract.* 2018;6(5):1726-1732.e6.
14. Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. *Ann Allergy, Asthma Immunol.* 2010;105(2):168-173.
15. Bousquet J, Devillier P, Arnavelhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. *Allergy Eur J Allergy Clin Immunol.* 2018;73(9):1763-1774.
16. Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. *Int Arch Allergy Immunol.* 2013;161(4):369-377.
17. Harrow B, Sedaghat AR, Caldwell-Tarr A, Dufour R. A Comparison of Health Care Resource Utilization and Costs for Patients with Allergic Rhinitis on Single-Product or Free-Combination Therapy of Intranasal Steroids and Intranasal Antihistamines. *J Manag Care Spec Pharm.* 2016;1:11.
18. Bédard A, Basagaña X, Anto JM, et al. Mobile technology offers novel insights on control and treatment of allergic rhinitis. The MASK study. *J Allergy Clin Immunol.* April 2019.
19. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. *J Allergy Clin Immunol.* 2006;117(1):158-162.
20. Price D, Scadding G, Ryan D, et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. *Clin Transl Allergy.* 2015;5(1).
21. Klimek L, Bachert C, Stjärne P, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study. *Allergy Asthma Proc.* 2016;37(5):376-386.
22. Baiardi I, Braido F, Bonini M, Compalati E, Canonica GW. Why do doctors and patients not follow guidelines? *Curr Opin Allergy Clin Immunol.* 2009;9(3):228-233.
23. Mendifitto E, Costa E, Midão L, et al. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. *Clin Exp Allergy.* 2019;49(4):442-460.
24. Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: Allergic rhinitis is not a trivial disease. *Curr Opin Allergy Clin Immunol.* 2008;8(1):1-9.
25. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2010 Revision. *J Allergy Clin Immunol.* 2010;126(3):466-476.